SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
155.20    2.40 (1.57%)
Bid:
155.00
Ask:
155.40
Spread: 0.40 (0.258%)
Market Cap: £888.23m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Interim Management Statement

25 Oct 2013 07:00

RNS Number : 3576R
Elementis PLC
25 October 2013
 



 

 

Elementis - Interim Management Statement

 

Elementis plc (ELM.L, "Elementis" or "the Group"), the Global Specialty Chemicals Company, today issues its Interim Management Statement for the three months ended 30 September 2013.

 

Commenting on the Group's performance Group Chief Executive, David Dutro, said:

"Elementis is pleased to report another resilient performance in spite of an economic background where growth is turning out to be slower than generally anticipated. The Group's strategy of creating its own growth opportunities, combined with its strong, diverse market positions and a return to more normal trading patterns in oilfield drilling are the key drivers of the Group's 12 per cent sales growth in the current quarter, compared to the same period last year. The integration of the Group's two recent acquisitions, Watercryl in Brazil and Hi-Mar in the US, is progressing well and the second and final phase of our new coatings additives plant in North America is well underway. These investments strengthen the broad geographic presence and enhance the Group's exciting market positions and will support further growth over the medium term."

 

 

Specialty Products sales improved by 15 per cent, or 8 per cent excluding acquisitions and currency.

 

· In coatings, sales in North America were higher by 12 per cent, mainly due to the acquisition of Hi-Mar earlier in the year. In Asia Pacific, sales increased by 11 per cent as the business continued to benefit from its market position in China, experiencing strong demand from local high-end industrial markets. Latin American sales increased by 68 per cent, driven by the acquisition of Watercryl in September 2012, and good progress is being made in expanding Watercryl sales outside of Brazil. In Europe, underlying economic conditions continue to be subdued as headline sales improved by 3 per cent, with currency contributing 4 per cent.

 

· In personal care, the business continued to benefit from the initiatives of a refocused management structure, with additional resources in new geographies and new product launches. As a result, sales improved by 16 per cent or 13 per cent excluding currency.

 

· Sales to the oil and gas drilling sector continued to demonstrate a sustained recovery following the impact of industry destocking in the latter part of 2012, maintaining the robust pace reported for the first six months of the year. Consequently, sales to this sector were at a similar level to the average quarterly sales in the first half of this year and 35 per cent ahead of the same period last year.

 

· Operating margin in the third quarter was similar to that reported for the first six months of the year as overall pricing and contribution margins remained stable.

 

As expected, following the planned maintenance shutdown in the early part of the year, Chromium trading patterns in the current quarter returned to more normal levels. Chromium sales in the quarter were 5 per cent ahead of the same period last year and at a similar level to the second quarter of the current year. As production volumes and plant utilisation returned to more normal levels, margins improved compared to the first half of the year and operating margin for the full year is expected to be in the range of 24-26 per cent. Consistent with our strategy of stable earnings and cash flow, we expect the performance of Chromium in the second half of 2013 will be similar to the second half of last year.

 

Cash flow continues to be a positive aspect of the Group's performance and it is anticipated that the end of year balance sheet will show a net cash balance of at least $30 million.

 

Overall we remain confident in the Group's ability to deliver growth that is in excess of the underlying economies in which it operates and expect our full year earnings per share to be in line with market expectations.

 

 

 

 

 

Enquiries:

Elementis + 44 (0) 207 408 9300

Brian Taylorson, Finance Director

  

FTI Consulting

 + 44 (0) 207 831 3113

Deborah Scott

Matthew Cole

  

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUSOVROUARUAA
Date   Source Headline
2nd Aug 20227:00 amRNSHalf-year Report
1st Aug 202211:08 amRNSTotal Voting Rights
21st Jul 20223:14 pmRNSHolding(s) in Company
1st Jul 20229:47 amRNSTotal Voting Rights
20th Jun 20221:54 pmRNSHolding(s) in Company
17th Jun 20224:35 pmRNSPrice Monitoring Extension
3rd May 202210:27 amRNSTotal Voting Rights
3rd May 20227:00 amRNSCompany Secretary Change
26th Apr 202212:28 pmRNSResult of AGM
26th Apr 20227:00 amRNSAGM Trading Statement
5th Apr 20224:17 pmRNSDirector/PDMR Shareholding
23rd Mar 20223:52 pmRNSAdditional Listing
22nd Mar 20224:18 pmRNSAnnual Financial Report & Notice of AGM
15th Mar 20227:53 amRNSDirectorate Change
8th Mar 202212:18 pmRNSDirector/PDMR Shareholding
8th Mar 202212:17 pmRNSDirector/PDMR Shareholding
8th Mar 202211:47 amRNSHolding(s) in Company
8th Mar 202210:43 amRNSDirector/PDMR Shareholding
8th Mar 202210:39 amRNSDirector/PDMR Shareholding
7th Mar 20223:26 pmRNSHolding(s) in Company
3rd Mar 20227:00 amRNSPreliminary results year ended 31 December 2021
1st Mar 20222:03 pmRNSDirector Declaration
1st Mar 202211:18 amRNSBlock listing Interim Review
18th Jan 20227:00 amRNSTrading Update
10th Jan 20221:20 pmRNSHolding(s) in Company
4th Jan 202211:48 amRNSTotal Voting Rights
1st Dec 202111:10 amRNSTotal Voting Rights
10th Nov 202112:20 pmRNSHolding(s) in Company
3rd Nov 202111:25 amRNSHolding(s) in Company
1st Nov 20211:44 pmRNSTotal Voting Rights
28th Oct 20217:00 amRNSQ3 Trading Update
19th Oct 20216:10 pmRNSDirector Declaration
5th Oct 20218:42 amRNSDirector Declaration
1st Sep 20219:49 amRNSBlock listing Interim Review
2nd Aug 202110:22 amRNSTotal Voting Rights
29th Jul 20217:00 amRNSDirectorate Change
29th Jul 20217:00 amRNSHalf-year Report
5th Jul 202110:15 amRNSTotal Voting Rights
25th Jun 20212:59 pmRNSHolding(s) in Company
23rd Jun 20212:56 pmRNSDirector Declaration
1st Jun 202110:06 amRNSTotal Voting Rights
13th May 20213:39 pmRNSResult of AGM
13th May 20217:00 amRNSAGM Trading Statement
22nd Apr 20213:26 pmRNSAdditional Listing
20th Apr 20214:18 pmRNSResponse to Innospec Inc. announcement
20th Apr 20212:36 pmRNSPress Speculation Re Possible Offer for Elementis
9th Apr 20215:15 pmRNSAnnual Financial Report
7th Apr 20215:31 pmRNSDirector/PDMR Shareholding
1st Apr 20218:49 amRNSDirector/PDMR Shareholding
30th Mar 20214:08 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.